Liquid Biopsy Market Overview

The report is titled as ‘Liquid Biopsy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the liquid biopsy market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. liquid biopsy market is expected to grow with significant rate in the near future.

The global liquid biopsy market in 2020 is estimated for more than US$ 1,013.6 Mn and expected to reach a value of US$ 2,563.9 Mn by 2028 with a significant CAGR of 12.3%.

Liquid Biopsy Market Definition

The liquid biopsy is a largely non-invasive clinical test performed in order to identify the cancer cells from the tumor that are flowing in the blood or in the DNA from tumor cells that are mixed in blood. The liquid biopsy is a medical procedure performed on the sample of blood of a patient, in order to diagnose cancer at an initial stage or it may help in monitoring the efficiency of the treatment provided to the patients as well as in planning the further treatment.

Also, if the liquid biopsy procedure is performed multiple times by regularly taking blood samples over time, it is also likely to assist the healthcare professionals to monitor the molecular changes taking place in the tumor of the patient.

Owing to all such factors, the liquid biopsy considerably has numerous benefits which elevates its demand all across the world. Attributing to which, the global liquid biopsy market is projected to witness significant growth in the forthcoming years.

Liquid Biopsy Market Dynamics

The growing prevalence of cancer among the population is one of the major aspects that is projected to boost the growth of the global liquid biopsy market in the near future. For example, In 2018, around 18.1 million new cases and 9.6 million fatalities were recorded due to cancer globally, as per the World Health Organization.

In addition, the liquid biopsy is the medical procedure with a massive number of benefits, which is why it is preferred excessively, thereby fueling the growth of the global liquid biopsy market. One of the most beneficial aspect of the liquid biopsy is that it is a non-invasive procedure and thus, it prevent the painful extraction of the sample of tissues and therefore eradicate the pain affiliated with the process, which in turn is expected to further accelerate the growth of the global liquid biopsy market in the upcoming future.

By the same token, there is a substantial number of favorable trials of liquid biopsy owing to the constant advancements, which is also acting as a positive factor in order to further augment the growth of the global liquid biopsy market during the forecast timeframe.

However, the constant research and development activities has resulted in other alternatives for liquid biopsy, which may hold back the growth of the global liquid biopsy market in the coming years.

Liquid Biopsy Market Key Players

Some of the key participating players in the liquid biopsy market are Biocept, Inc., Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Menarini-Silicon Biosystems, Trovagene, Inc., Guardant Health, Inc., Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc.

Liquid Biopsy Market Segmentation

The liquid biopsy market is segmented on the basis of circulating biomarker, cancer type, end user, product type, and by region.

On the basis of circulating biomarker, the global liquid biopsy market is segmented into

•    Circulating Tumor Cells 

•    Circulating Tumor DNA (CTDNA) 

•    Cell-Free DNA 

•    Extracellular Vesicles (Evs) 

•    Other Circulating Biomarkers

While on the basis of cancer type the market can be segmented into

•    Lung Cancer

•    Breast Cancer

•    Colorectal Cancer

•    Prostate Cancer

•    Liver Cancer

•    Other Cancers

On the basis of Clinical Application the market can be segmented into

•    Early Cancer Screening

•    Therapy Selection

•    Treatment Monitoring 

•    Recurrence Monitoring

On the basis of Product the market is segmented into

•    Assay Kits 

•    Instruments

On the basis of End User the market is segmented into

•    Reference Laboratories 

•    Hospitals and Physician Laboratories 

•    Academic and Research Centers 

•    Other

On the basis of Region, the global liquid biopsy market is segmented into

•    North America (U.S., Canada)

•    Latin America (Brazil, Mexico, Argentina, Rest of Latin America)

•    Europe (U.K., Germany, Italy, France, Spain, Russia, Poland, BENELUX, NORDIC)

•    Asia Pacific (China, India, Japan, Australia and New Zealand, South Korea, ASEAN, Rest of Asia)

•    Middle East (GCC Countries, Israel, Oman, Rest of Middle East)

•    Africa (South Africa, Egypt, North Africa, Rest of Africa)

MMC Overview on Liquid Biopsy Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the Liquid Biopsy market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Liquid Biopsy

•    Advantages of Liquid Biopsy

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Liquid Biopsy Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Liquid Biopsy Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Liquid Biopsy Market Snapshot

2.4.    Global Liquid Biopsy Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Liquid Biopsy Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Liquid Biopsy Market, By Product type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Product type

3.1.2.    BPS Analysis, By Product type

3.2.    Market Revenue (US$Mn) Forecast, By Product type

3.2.1.    Assay Kits 

3.2.2.    Instruments

3.3.    Global Liquid Biopsy Market Attractiveness Index, By Product type

4.    Global Liquid Biopsy Market, By Circulating Biomarker

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Circulating Biomarker

4.1.2.    BPS Analysis, By Circulating Biomarker

4.2.    Market Revenue (US$Mn) Forecast, By Circulating Biomarker

4.2.1.    Circulating Tumor Cells 

4.2.2.    Circulating Tumor DNA (CTDNA) 

4.2.3.    Cell-Free DNA 

4.2.4.    Extracellular Vesicles (Evs) 

4.2.5.    Other Circulating Biomarkers

4.3.    Global Liquid Biopsy Market Attractiveness Index, By Circulating Biomarker

5.    Global Liquid Biopsy Market, By Cancer Type

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Cancer Type

5.1.2.    BPS Analysis, By Cancer Type

5.2.    Market Revenue (US$Mn) Forecast, By Cancer Type

5.2.1.    Lung Cancer

5.2.2.    Breast Cancer

5.2.3.    Colorectal Cancer

5.2.4.    Prostate Cancer

5.2.5.    Liver Cancer

5.2.6.    Other Cancers

5.3.    Global Liquid Biopsy Market Attractiveness Index, By Cancer Type

6.    Global Liquid Biopsy Market, By Clinical Application

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Clinical Application

6.1.2.    BPS Analysis, By Clinical Application

6.2.    Market Revenue (US$Mn) Forecast, By Clinical Application

6.2.1.    Early Cancer Screening

6.2.2.    Therapy Selection

6.2.3.    Treatment Monitoring 

6.2.4.    Recurrence Monitoring

6.3.    Global Liquid Biopsy Market Attractiveness Index, By Clinical Application

7.    Global Liquid Biopsy Market, By End User

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By End User

7.1.2.    BPS Analysis, By End User

7.2.    Market Revenue (US$Mn) Forecast, By End User

7.2.1.    Reference Laboratories 

7.2.2.    Hospitals and Physician Laboratories 

7.2.3.    Academic and Research Centers 

7.2.4.    Other

7.3.    Global Liquid Biopsy Market Attractiveness Index, By End User

8.    Global Liquid Biopsy Market, By Region

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Region

8.1.2.    BPS Analysis, By Region

8.2.    Market Revenue (US$Mn) Forecast, By Region

8.2.1.    North America

8.2.2.    Latin America

8.2.3.    Europe

8.2.4.    Asia Pacific

8.2.5.    Middle East

8.2.6.    Africa

8.3.    Global Liquid Biopsy Market Attractiveness Index, By Region

9.    North America Liquid Biopsy Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market Revenue (US$Mn) Forecast, By Country

9.2.1.    U.S. Liquid Biopsy Market

9.2.2.    Canada Liquid Biopsy Market

9.3.    North America Liquid Biopsy Market, By Product type

9.3.1.    Assay Kits 

9.3.2.    Instruments

9.4.    North America Liquid Biopsy Market, By Circulating Biomarker

9.4.1.    Circulating Tumor Cells 

9.4.2.    Circulating Tumor DNA (CTDNA) 

9.4.3.    Cell-Free DNA 

9.4.4.    Extracellular Vesicles (Evs) 

9.4.5.    Other Circulating Biomarkers

9.5.    North America Liquid Biopsy Market, By Cancer Type

9.5.1.    Lung Cancer

9.5.2.    Breast Cancer

9.5.3.    Colorectal Cancer

9.5.4.    Prostate Cancer

9.5.5.    Liver Cancer

9.5.6.    Other Cancers

9.6.    North America Liquid Biopsy Market, By Clinical Application

9.6.1.    Early Cancer Screening

9.6.2.    Therapy Selection

9.6.3.    Treatment Monitoring 

9.6.4.    Recurrence Monitoring

9.7.    North America Liquid Biopsy Market, By End User

9.7.1.    Reference Laboratories 

9.7.2.    Hospitals and Physician Laboratories 

9.7.3.    Academic and Research Centers 

9.7.4.    Other

9.8.    North America Liquid Biopsy Market Attractiveness Index

9.8.1.    By Country

9.8.2.    By Product type

9.8.3.    By Circulating Biomarker

9.8.4.    By Cancer Type

9.8.5.    By End User

10.    Latin America Liquid Biopsy Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    Brazil Liquid Biopsy Market

10.2.2.    Mexico Liquid Biopsy Market

10.2.3.    Argentina Liquid Biopsy Market

10.2.4.    Rest of Latin America Liquid Biopsy Market

10.3.    Latin America Liquid Biopsy Market, By Product type

10.3.1.    Assay Kits

10.3.2.    Instruments

10.4.    Latin America Liquid Biopsy Market, By Circulating Biomarker

10.4.1.    Circulating Tumor Cells 

10.4.2.    Circulating Tumor DNA (CTDNA) 

10.4.3.    Cell-Free DNA 

10.4.4.    Extracellular Vesicles (Evs) 

10.4.5.    Other Circulating Biomarkers

10.5.    Latin America Liquid Biopsy Market, By Cancer Type

10.5.1.    Lung Cancer

10.5.2.    Breast Cancer

10.5.3.    Colorectal Cancer

10.5.4.    Prostate Cancer

10.5.5.    Liver Cancer

10.5.6.    Other Cancers

10.6.    Latin America Liquid Biopsy Market, By Clinical Application

10.6.1.    Early Cancer Screening

10.6.2.    Therapy Selection

10.6.3.    Treatment Monitoring 

10.6.4.    Recurrence Monitoring

10.7.    Latin America Liquid Biopsy Market, By End User

10.7.1.    Reference Laboratories 

10.7.2.    Hospitals and Physician Laboratories 

10.7.3.    Academic and Research Centers 

10.7.4.    Other

10.8.    Latin America Liquid Biopsy Market Attractiveness Index

10.8.1.    By Country

10.8.2.    By Product type

10.8.3.    By Circulating Biomarker

10.8.4.    By Cancer Type

10.8.5.    By End User

11.    Europe Liquid Biopsy Market Analysis and Forecast, 2020–2028

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    U.K. Liquid Biopsy Market

11.2.2.    Germany Liquid Biopsy Market

11.2.3.    Italy Liquid Biopsy Market

11.2.4.    France Liquid Biopsy Market

11.2.5.    Spain Liquid Biopsy Market

11.2.6.    Russia Liquid Biopsy Market

11.2.7.    Poland Liquid Biopsy Market

11.2.8.    BENELUX Liquid Biopsy Market

11.2.9.    NORDIC Liquid Biopsy Market

11.2.10.    Rest of Europe Liquid Biopsy Market

11.3.    Europe Liquid Biopsy Market, By Product type

11.3.1.    Assay Kits 

11.3.2.    Instruments

11.4.    Europe Liquid Biopsy Market, By Circulating Biomarker

11.4.1.    Circulating Tumor Cells 

11.4.2.    Circulating Tumor DNA (CTDNA) 

11.4.3.    Cell-Free DNA 

11.4.4.    Extracellular Vesicles (Evs) 

11.4.5.    Other Circulating Biomarkers

11.5.    Europe Liquid Biopsy Market, By Cancer Type

11.5.1.    Lung Cancer

11.5.2.    Breast Cancer

11.5.3.    Colorectal Cancer

11.5.4.    Prostate Cancer

11.5.5.    Liver Cancer

11.5.6.    Other Cancers

11.6.    Europe Liquid Biopsy Market, By Clinical Application

11.6.1.    Early Cancer Screening

11.6.2.    Therapy Selection

11.6.3.    Treatment Monitoring 

11.6.4.    Recurrence Monitoring

11.7.    Europe Liquid Biopsy Market, By End User

11.7.1.    Reference Laboratories 

11.7.2.    Hospitals and Physician Laboratories 

11.7.3.    Academic and Research Centers 

11.7.4.    Other

11.8.    Europe Liquid Biopsy Market Attractiveness Index

11.8.1.    By Country

11.8.2.    By Product type

11.8.3.    By Circulating Biomarker

11.8.4.    By Cancer Type

11.8.5.    By End User

12.    Asia Pacific Liquid Biopsy Market Analysis and Forecast, 2020–2028

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    China Liquid Biopsy Market

12.2.2.    India Liquid Biopsy Market

12.2.3.    Japan Liquid Biopsy Market

12.2.4.    Australia and New Zealand Liquid Biopsy Market

12.2.5.    South Korea Liquid Biopsy Market

12.2.6.    ASEAN Liquid Biopsy Market

12.2.7.    Rest of Asia Pacific Liquid Biopsy Market

12.3.    Asia Pacific Liquid Biopsy Market, By Product type

12.3.1.    Assay Kits 

12.3.2.    Instruments

12.4.    Asia Pacific Liquid Biopsy Market, By Circulating Biomarker

12.4.1.    Circulating Tumor Cells 

12.4.2.    Circulating Tumor DNA (CTDNA) 

12.4.3.    Cell-Free DNA 

12.4.4.    Extracellular Vesicles (Evs) 

12.4.5.    Other Circulating Biomarkers

12.5.    Asia Pacific Liquid Biopsy Market, By Cancer Type

12.5.1.    Lung Cancer

12.5.2.    Breast Cancer

12.5.3.    Colorectal Cancer

12.5.4.    Prostate Cancer

12.5.5.    Liver Cancer

12.5.6.    Other Cancers

12.6.    Asia Pacific Liquid Biopsy Market, By Clinical Application

12.6.1.    Early Cancer Screening

12.6.2.    Therapy Selection

12.6.3.    Treatment Monitoring 

12.6.4.    Recurrence Monitoring

12.7.    Asia Pacific Liquid Biopsy Market, By End User

12.7.1.    Reference Laboratories 

12.7.2.    Hospitals and Physician Laboratories 

12.7.3.    Academic and Research Centers 

12.7.4.    Other

12.8.    Asia Pacific Liquid Biopsy Market Attractiveness Index

12.8.1.    By Country

12.8.2.    By Product type

12.8.3.    By Circulating Biomarker

12.8.4.    By Cancer Type

12.8.5.    By End User

13.    Middle East Liquid Biopsy Market, By Region

13.1.    Introduction

13.1.1.    Annual Growth Rate Comparison, By Country

13.1.2.    BPS Analysis, By Country

13.2.    Market (US$Mn) Forecast, By Country

13.2.1.    GCC Countries Liquid Biopsy Market

13.2.2.    Israel Liquid Biopsy Market

13.2.3.    Oman Liquid Biopsy Market

13.2.4.    Rest of Middle East Liquid Biopsy Market

13.3.    Middle East Liquid Biopsy Market, By Product type

13.3.1.    Assay Kits 

13.3.2.    Instruments

13.4.    Middle East Liquid Biopsy Market, By Circulating Biomarker

13.4.1.    Circulating Tumor Cells 

13.4.2.    Circulating Tumor DNA (CTDNA) 

13.4.3.    Cell-Free DNA 

13.4.4.    Extracellular Vesicles (Evs) 

13.4.5.    Other Circulating Biomarkers

13.5.    Middle East Liquid Biopsy Market, By Cancer Type

13.5.1.    Lung Cancer

13.5.2.    Breast Cancer

13.5.3.    Colorectal Cancer

13.5.4.    Prostate Cancer

13.5.5.    Liver Cancer

13.5.6.    Other Cancers

13.6.    Middle East Liquid Biopsy Market, By Clinical Application

13.6.1.    Early Cancer Screening

13.6.2.    Therapy Selection

13.6.3.    Treatment Monitoring 

13.6.4.    Recurrence Monitoring

13.7.    Middle East Liquid Biopsy Market, By End User

13.7.1.    Reference Laboratories 

13.7.2.    Hospitals and Physician Laboratories 

13.7.3.    Academic and Research Centers 

13.7.4.    Other

13.8.    Middle East Liquid Biopsy Market Attractiveness Index

13.8.1.    By Country

13.8.2.    By Product type

13.8.3.    By Circulating Biomarker

13.8.4.    By Cancer Type

13.8.5.    By End User

14.    Africa Liquid Biopsy Market, By Region

14.1.    Introduction

14.1.1.    Annual Growth Rate Comparison, By Country

14.1.2.    BPS Analysis, By Country

14.2.    Market (US$Mn) Forecast, By Country

14.2.1.    South Africa Liquid Biopsy Market

14.2.2.    Egypt Liquid Biopsy Market

14.2.3.    North Africa Liquid Biopsy Market

14.2.4.    Rest of Africa Liquid Biopsy Market

14.3.    Africa Liquid Biopsy Market, By Product type

14.3.1.    Assay Kits 

14.3.2.    Instruments

14.4.    Africa Liquid Biopsy Market, By Circulating Biomarker

14.4.1.    Circulating Tumor Cells 

14.4.2.    Circulating Tumor DNA (CTDNA) 

14.4.3.    Cell-Free DNA 

14.4.4.    Extracellular Vesicles (Evs) 

14.4.5.    Other Circulating Biomarkers

14.5.    Africa Liquid Biopsy Market, By Cancer Type

14.5.1.    Lung Cancer

14.5.2.    Breast Cancer

14.5.3.    Colorectal Cancer

14.5.4.    Prostate Cancer

14.5.5.    Liver Cancer

14.5.6.    Other Cancers

14.6.    Africa Liquid Biopsy Market, By Clinical Application

14.6.1.    Early Cancer Screening

14.6.2.    Therapy Selection

14.6.3.    Treatment Monitoring 

14.6.4.    Recurrence Monitoring

14.7.    Africa Liquid Biopsy Market, By End User

14.7.1.    Reference Laboratories 

14.7.2.    Hospitals and Physician Laboratories 

14.7.3.    Academic and Research Centers 

14.7.4.    Other

14.8.    Africa Liquid Biopsy Market Attractiveness Index

14.8.1.    By Country

14.8.2.    By Product type

14.8.3.    By Circulating Biomarker

14.8.4.    By Cancer Type

14.8.5.    By End User

15.    Recommendation

15.1.    Market Strategy

16.    Competitive Landscape

16.1.    Competition Dashboard

16.2.    List and Company Overview of Global Key Players

16.3.    Company Profiles

16.3.1.    Biocept, Inc.

16.3.1.1.    Company Overview

16.3.1.2.    Financial Overview

16.3.1.3.    Product Portfolio

16.3.1.4.    Key Developments

16.3.1.5.    Business Strategies

16.3.2.    Qiagen N.V.

16.3.3.    Roche Diagnostics

16.3.4.    Bio-Rad Laboratories, Inc.

16.3.5.    Myriad Genetics, Inc.

16.3.6.    Menarini-Silicon Biosystems

16.3.7.    Trovagene, Inc.

16.3.8.    Guardant Health, Inc.

16.3.9.    Mdxhealth SA

16.3.10.    Genomic Health, Inc.

16.3.11.    Raindance Technologies, Inc.

16.3.12.    Thermo Fisher Scientific Inc.

16.3.13.    Illumina, Inc.

17.    Acronyms